Related Experiment Video
Updated: Apr 19, 2026
Mouse Microsurgery Infusion Technique for Targeted Substance Delivery into the CNS via the Internal Carotid Artery
Published on: January 31, 2017
Microtubule-Targeting Agents Enter the Central Nervous System (CNS): Double-edged Swords for Treating CNS Injury and
1Brain Science Institute, Korea Institute of Science and Technology, Seoul, Korea. ; Department of Neuroscience, Korea University of Science and Technology, Daejeon, Korea.
Abstract:
Microtubules have been among the most successful targets in anticancer therapy and a large number of microtubule-targeting agents (MTAs) are in various stages of clinical development for the treatment of several malignancies. Given that injury and diseases in the central nervous system (CNS) are accompanied by acute or chronic disruption of the structural integrity of neurons and that microtubules provide structural support for the nervous system at cellular and intracellular levels, microtubules are emerging as potential therapeutic targets for treating CNS disorders. It has been postulated that exogenous application of MTAs might prevent the breakdown or degradation of microtubules after injury or during neurodegeneration, which will thereby aid in preserving the structural integrity and function of the nervous system. Here we review recent evidence that supports this notion and also discuss potential risks of targeting microtubules as a therapy for treating nerve injury and neurodegenerative diseases.
Insights
Microtubule-targeting agents (MTAs) show promise for treating central nervous system (CNS) disorders by preserving neuronal structure after injury or during neurodegeneration. Further research is needed to explore their therapeutic potential and risks.
Area of Science:
- Neuroscience
- Pharmacology
- Oncology
Background:
- Microtubules are crucial for neuronal structural integrity in the central nervous system (CNS).
- Microtubule-targeting agents (MTAs) are established anticancer drugs.
- CNS injury and neurodegeneration disrupt neuronal microtubules.
Purpose of the Study:
- To review evidence supporting MTAs as a therapeutic strategy for CNS disorders.
- To discuss the potential benefits and risks of using MTAs in nerve injury and neurodegenerative diseases.
Main Methods:
- Literature review of preclinical and clinical studies on MTAs in CNS disorders.
- Analysis of mechanisms underlying microtubule disruption in CNS conditions.
- Evaluation of studies investigating MTA efficacy and safety in neurological contexts.
Main Results:
- Evidence suggests MTAs can prevent microtubule breakdown in models of nerve injury and neurodegeneration.
- MTAs may preserve neuronal structural integrity and function.
- Potential risks associated with targeting microtubules in the CNS require careful consideration.
Conclusions:
- Microtubules represent a promising therapeutic target for CNS disorders.
- MTAs warrant further investigation for treating nerve injury and neurodegenerative diseases.
- Balancing efficacy and potential neurotoxicity is critical for MTA-based CNS therapies.
More Related Videos
11:51Systemic and Local Drug Delivery for Treating Diseases of the Central Nervous System in Rodent Models
Published on: August 16, 2010
04:02Author Spotlight: Developing Precise and Clinically Relevant Models for Studying Secondary Degeneration in Traumatic Optic Neuropathy
Published on: November 29, 2024
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:29Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:10Drugs that Destabilize Microtubules